Crizanlizumab has been found to reduce pain in patients with sickle cell disease who were facing the brunt of vaso-occlusive crisis (VOC). The vaso-occlusive crisis, or sickle cell crisis, is believed to be ischemic tissue injury caused due to obstruction of blood flow by sickled erythrocytes.
Vaso-occlusive crisis make up for the most common and the most painful complication for people with sickle cell disease. Also, this crisis is the main reason patients visit a hospital for getting treatment. They lead to increased morbidity and mortality and can cause stroke or multi organ damage or failure. At present the therapeutic options to tackle vaso-occlusive crisis are pretty limited.
Samit Hirawat, MD, the Head of Novartis Oncology Global Drug Development expressed hopes that the insights gained from the analysis would bring crizanlizumab to the status of an important therapeutic option for sickle cell patients who need step changes in medical innovation.
Read the complete report here